Brand Name | Status | Last Update |
---|---|---|
simulect | Biologic Licensing Application | 2025-01-21 |
Expiration | Code | ||
---|---|---|---|
basiliximab, Simulect, Novartis Pharmaceuticals Corporation | |||
2105-05-12 | Orphan excl. |
Code | Description |
---|---|
J0480 | Injection, basiliximab, 20 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney transplantation | D016030 | — | — | 2 | 7 | 10 | 9 | — | 25 |
Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | 5 | 4 | — | 9 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | 1 | 2 | — | 3 |
Infections | D007239 | EFO_0000544 | — | — | — | 1 | 1 | — | 2 |
Renal insufficiency | D051437 | — | N19 | — | 1 | 1 | 1 | — | 2 |
Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | — | — | — | 1 | — | 1 |
Communicable diseases | D003141 | — | — | — | — | — | 1 | — | 1 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | — | 1 |
Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Organ transplantation | D016377 | — | — | — | — | 2 | — | — | 2 |
Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
Interstitial lung diseases | D017563 | EFO_0004244 | J84.9 | — | — | 1 | — | — | 1 |
Hepatitis c | D006526 | — | B19.2 | — | — | 1 | — | — | 1 |
Hepatitis | D006505 | — | K75.9 | — | — | 1 | — | — | 1 |
Graft rejection | D006084 | — | — | — | — | 1 | — | — | 1 |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | — | 1 |
Emphysema | D004646 | EFO_0000464 | J43 | — | — | 1 | — | — | 1 |
Bronchiolitis obliterans | D001989 | EFO_0007183 | J44.81 | — | — | 1 | — | — | 1 |
Bronchiolitis | D001988 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Virus diseases | D014777 | — | B34 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
Immunosuppression therapy | D007165 | — | — | — | — | — | — | 1 | 1 |
Polyomavirus infections | D027601 | EFO_0007451 | — | — | — | — | — | 1 | 1 |
Viremia | D014766 | — | B34.9 | — | — | — | — | 1 | 1 |
Graft vs host disease | D006086 | — | D89.81 | — | — | — | — | 1 | 1 |
Hematopoietic stem cell transplantation | D018380 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Basiliximab |
INN | basiliximab |
Description | Basiliximab (chimeric mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >3IU3:A,C,H|Heavy chain of Fab fragment of Basiliximab
QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYME
LSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA
LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP
>3IU3:B,D,L|Light chain of Fab fragment of Basiliximab
QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAE
DAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV
TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE |
PDB | 3IU3 |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201439 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00074 |
UNII ID | 9927MT646M (ChemIDplus, GSRS) |